Kamada Ltd. (TLV:KMDA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 1.30B |
| Revenue (ttm) | 571.15M |
| Net Income (ttm) | 64.05M |
| Shares Out | 57.68M |
| EPS (ttm) | 1.08 |
| PE Ratio | 20.96 |
| Forward PE | 18.81 |
| Dividend | 0.73 (3.27%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 21,363 |
| Average Volume | 54,083 |
| Open | 2,250.00 |
| Previous Close | 2,262.00 |
| Day's Range | 2,231.00 - 2,278.00 |
| 52-Week Range | 2,004.00 - 3,045.00 |
| Beta | 0.06 |
| RSI | 44.25 |
| Earnings Date | Nov 12, 2025 |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f... [Read more]
Full Company ProfileFinancial Performance
In 2024, Kamada's revenue was $160.95 million, an increase of 12.93% compared to the previous year's $142.52 million. Earnings were $14.46 million, an increase of 74.58%.
Financial numbers in USD Financial StatementsNews
3 Reasons Why Growth Investors Shouldn't Overlook Kamada (KMDA)
Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
Kamada (KMDA) could produce exceptional returns because of its solid growth attributes.
Kamada: Earnings Expansion Cycle With Embedded Margin Of Safety
KMDA remains a buy as it delivers strong earnings growth, robust cash generation, and trades at a discount to healthcare peers with an attractive FCF yield. Q2 results confirm ongoing operating levera...
Kamada Ltd. (KMDA) Q2 2025 Earnings Call Transcript
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ: EVO) is projected to report quarterly loss at $0.12 per share on revenue of $238.88 million. • Elbit Systems (NASDAQ: ESLT) is projected to repo...
Kamada Q2 2025 Earnings Preview
An Overview of Kamada's Earnings
Kamada (NASDAQ: KMDA) is set to give its latest quarterly earnings report on Wednesday, 2025-08-13. Here's what investors need to know before the announcement. Analysts estimate that Kamada will repo...
Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd.
Kamada confirms continuous business operations despite recent events in Middle East
Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East
REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for r...
Kamada Q1 Results: Double-Digit Growth, Company Reiterates Guidance As It Hits Multiple Milestones Including Plasma Business Expansion
Kamada Ltd. (NASDAQ: KMDA) recently reported earnings for the first quarter of 2025, which saw revenue up 17% and Adjusted EBITDA up 54% year-over-year. The results help position Kamada to drive grow...
Kamada Ltd. (KMDA) Q1 2025 Earnings Call Transcript
Kamada beats top-line estimates; reaffirms FY25 outlook
Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability
REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for ra...
Earnings Scheduled For May 14, 2025
Companies Reporting Before The Bell • Cellebrite DI (NASDAQ: CLBT) is expected to report quarterly earnings at $0.09 per share on revenue of $109.36 million. • Banco Latinoamericano (NYSE: BLX) is p...
Kamada Q1 2025 Earnings Preview
Earnings Preview For Kamada
Kamada (NASDAQ: KMDA) is set to give its latest quarterly earnings report on Wednesday, 2025-05-14. Here's what investors need to know before the announcement. Analysts estimate that Kamada will repo...
Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas
REHOVOT, Israel and HOBOKEN, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for ...
Kamada Announces Dividend After Record-Breaking Year, Anticipates Further Double-Digit Growth
Despite significant advancements in medical technologies and pharmaceutical advancements, certain conditions can only be addressed via plasma-derived medicines . This is especially the case for many r...
Kamada Ltd. (KMDA) Q4 2024 Earnings Call Transcript
Kamada Ltd. (NASDAQ:KMDA) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ETCompany ParticipantsBrian Ritchie – LifeSci AdvisorsAmir London – Chief...
Kamada declares $0.20 dividend
Kamada reports mixed Q4 results; reaffirms FY25 outlook
Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth
REHOVOT, Israel, and HOBOKEN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for...
Earnings Scheduled For March 5, 2025
Companies Reporting Before The Bell • Full Truck Alliance Co (NYSE: YMM) is projected to report quarterly earnings at $0.14 per share on revenue of $419.04 million. • Brown Forman Inc Class B Common ...